Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level

Tohru Nakagawa, Yae Kanai, Motokiyo Komiyama, Hiroyuki Fujimoto, Tadao Kakizoe

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prostate cancer mass screening using serum prostate-specific antigen (PSA) has been conducted widely in the world. However, little is known about the true prevalence of prostate cancer in the 'normal' PSA range (4.0 ng/mL or less). The aim of the present study was to elucidate the clinicopathological features of prostate cancer occurring in men with a wide range of PSA levels. The study comprised 349 male patients who underwent radical cystoprostatectomy for bladder cancer. Patients who had had treatment for known prostate cancer were excluded. Tissue specimens were reviewed microscopically. Ninety-one patients (26.1%) were found to have prostate cancer, and 68 (74.7%) of these 91 cancers were considered to be clinically significant. Both increasing patient age and PSA level were significantly correlated with an increased incidence of both all and significant prostate cancers. Sixty-five (21.9%) among 297 patients with PSA < 4.0 ng/mL had prostate cancer, and 45 (69.2%) of the 65 cancers were significant cancers. Eighteen patients had prostate cancers 0.5 mL or more in volume. Among the 18 patients, the PSA level was 4 ng/mL or more in 11, and 3 ng/mL or more in 15. Our study shows that prostate cancer is a common finding in radical cystoprostatectomy specimens excised because of bladder cancers, and a significant proportion of these cancers are clinically significant. PSA still appears to be a useful screening tool for detecting prostate cancers with significant volume. (Cancer Sci 2009; 100: 1880-1884).

Original languageEnglish
Pages (from-to)1880-1884
Number of pages5
JournalCancer Science
Volume100
Issue number10
DOIs
Publication statusPublished - 2009 Oct
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Urinary Bladder Neoplasms
Prostatic Neoplasms
Serum
Neoplasms
Mass Screening
Early Detection of Cancer
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level. / Nakagawa, Tohru; Kanai, Yae; Komiyama, Motokiyo; Fujimoto, Hiroyuki; Kakizoe, Tadao.

In: Cancer Science, Vol. 100, No. 10, 10.2009, p. 1880-1884.

Research output: Contribution to journalArticle

@article{28651e5367cf4376983b463b2244bb14,
title = "Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level",
abstract = "Prostate cancer mass screening using serum prostate-specific antigen (PSA) has been conducted widely in the world. However, little is known about the true prevalence of prostate cancer in the 'normal' PSA range (4.0 ng/mL or less). The aim of the present study was to elucidate the clinicopathological features of prostate cancer occurring in men with a wide range of PSA levels. The study comprised 349 male patients who underwent radical cystoprostatectomy for bladder cancer. Patients who had had treatment for known prostate cancer were excluded. Tissue specimens were reviewed microscopically. Ninety-one patients (26.1{\%}) were found to have prostate cancer, and 68 (74.7{\%}) of these 91 cancers were considered to be clinically significant. Both increasing patient age and PSA level were significantly correlated with an increased incidence of both all and significant prostate cancers. Sixty-five (21.9{\%}) among 297 patients with PSA < 4.0 ng/mL had prostate cancer, and 45 (69.2{\%}) of the 65 cancers were significant cancers. Eighteen patients had prostate cancers 0.5 mL or more in volume. Among the 18 patients, the PSA level was 4 ng/mL or more in 11, and 3 ng/mL or more in 15. Our study shows that prostate cancer is a common finding in radical cystoprostatectomy specimens excised because of bladder cancers, and a significant proportion of these cancers are clinically significant. PSA still appears to be a useful screening tool for detecting prostate cancers with significant volume. (Cancer Sci 2009; 100: 1880-1884).",
author = "Tohru Nakagawa and Yae Kanai and Motokiyo Komiyama and Hiroyuki Fujimoto and Tadao Kakizoe",
year = "2009",
month = "10",
doi = "10.1111/j.1349-7006.2009.01267.x",
language = "English",
volume = "100",
pages = "1880--1884",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level

AU - Nakagawa, Tohru

AU - Kanai, Yae

AU - Komiyama, Motokiyo

AU - Fujimoto, Hiroyuki

AU - Kakizoe, Tadao

PY - 2009/10

Y1 - 2009/10

N2 - Prostate cancer mass screening using serum prostate-specific antigen (PSA) has been conducted widely in the world. However, little is known about the true prevalence of prostate cancer in the 'normal' PSA range (4.0 ng/mL or less). The aim of the present study was to elucidate the clinicopathological features of prostate cancer occurring in men with a wide range of PSA levels. The study comprised 349 male patients who underwent radical cystoprostatectomy for bladder cancer. Patients who had had treatment for known prostate cancer were excluded. Tissue specimens were reviewed microscopically. Ninety-one patients (26.1%) were found to have prostate cancer, and 68 (74.7%) of these 91 cancers were considered to be clinically significant. Both increasing patient age and PSA level were significantly correlated with an increased incidence of both all and significant prostate cancers. Sixty-five (21.9%) among 297 patients with PSA < 4.0 ng/mL had prostate cancer, and 45 (69.2%) of the 65 cancers were significant cancers. Eighteen patients had prostate cancers 0.5 mL or more in volume. Among the 18 patients, the PSA level was 4 ng/mL or more in 11, and 3 ng/mL or more in 15. Our study shows that prostate cancer is a common finding in radical cystoprostatectomy specimens excised because of bladder cancers, and a significant proportion of these cancers are clinically significant. PSA still appears to be a useful screening tool for detecting prostate cancers with significant volume. (Cancer Sci 2009; 100: 1880-1884).

AB - Prostate cancer mass screening using serum prostate-specific antigen (PSA) has been conducted widely in the world. However, little is known about the true prevalence of prostate cancer in the 'normal' PSA range (4.0 ng/mL or less). The aim of the present study was to elucidate the clinicopathological features of prostate cancer occurring in men with a wide range of PSA levels. The study comprised 349 male patients who underwent radical cystoprostatectomy for bladder cancer. Patients who had had treatment for known prostate cancer were excluded. Tissue specimens were reviewed microscopically. Ninety-one patients (26.1%) were found to have prostate cancer, and 68 (74.7%) of these 91 cancers were considered to be clinically significant. Both increasing patient age and PSA level were significantly correlated with an increased incidence of both all and significant prostate cancers. Sixty-five (21.9%) among 297 patients with PSA < 4.0 ng/mL had prostate cancer, and 45 (69.2%) of the 65 cancers were significant cancers. Eighteen patients had prostate cancers 0.5 mL or more in volume. Among the 18 patients, the PSA level was 4 ng/mL or more in 11, and 3 ng/mL or more in 15. Our study shows that prostate cancer is a common finding in radical cystoprostatectomy specimens excised because of bladder cancers, and a significant proportion of these cancers are clinically significant. PSA still appears to be a useful screening tool for detecting prostate cancers with significant volume. (Cancer Sci 2009; 100: 1880-1884).

UR - http://www.scopus.com/inward/record.url?scp=70349592991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349592991&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01267.x

DO - 10.1111/j.1349-7006.2009.01267.x

M3 - Article

C2 - 19659608

AN - SCOPUS:70349592991

VL - 100

SP - 1880

EP - 1884

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -